New TNF-α analogues: A powerful but less toxic biological tool against tumours

Cytokine

Volumn 9, Issue 8, 1997, Pages 597-604

  Novakovic S ^a   Menart, V ^b   Gaberc Porekar, V ^c   Stale A ^b   Sersa G ^a   Cemazar M ^a   Jezersek B ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b Lek dd   (Slovenia)

^c NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

Author keywords

Analogues; Antitumour activity; rhTNF ; Side effects

Indexed keywords

LK 801; LK 805; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FEMALE; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

ANIMALIA;

EID: 0031213573     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1997.0207     Document Type: Article

References (28)

1. 1. Carswell EA, Old LJ, Kassel RL, Green KS, Fiore N, Williamson B (1975) An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666-3670.
2. 2. Fiers W (1991) Tumor necrosis factor: characterization at the molecular, cellular and in vivo level. FEBS Lett 285:199-212.
3. 3. Novaković S, Jezeršek B (1995) Tumor necrosis factor-α (TNF-α): Biological activities and mechanisms of action. Radiol Oncol 29:25-43.
4. 4. Serša G (1994) Tumor necrosis factor-biological characteristics and applications in cancer therapy. Zdrav Vestn, 63 (Suppl. II):II-35 II-42.
5. 5. Le J, Vilček J (1987) Biology of disease. Tumor necrosis factor and interleukin-1: Cytokines with multiple overlapping biological activities. Lab Invest 56:234-248.
6. 6. Old LJ (1985) Tumor necrosis factor (TNF). Science 230:630-632.
7. 7. Beutler B, Cerami A (1988) Tumor necrosis cachexia, schock and inflammation: A common mediator. Annu Rev Biochem 57:505-518.
8. 8. Fahey TJ, Yoshioka T, Shires TG, Fantini GA (1996) The role of tumor necrosis factor and nitric oxide in the acute cardiovascular response to endotoxin. Ann Surg 223:63-69.
9. 9. Lienard D, Eggermont A, Schraffordt KH, Lejeune FJ (1993) High dose of rTNFα, rIFN-γ and melphalan in isolation perfusion produce 90% complete response in melanoma in transit metastases. In Fiers W, Buurman WA (eds) Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance, Karger, Basel, pp. 233-238.
10. 10. Eggermont A, Lienard D, Schraffordt KH, Rosenkaimer F, Lejeune FJ (1993) Treatments of iresectable soft tissue sarcomas of the limbs by isolation perfusion with high dose TNFα in combination with interferon-γ and melphalan. In Fiers W, Buurman WA (eds) Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance, Karger, Basel, pp. 239-243.
11. 11. Renard N, Lienard D, Lespagnard L, Eggermont A, Heimann R, Lejeune F (1994) Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumor necrosis factor alpha (rTNFα). Int J Cancer 57:656-663.
12. 12. Vaglini M, Belli F, Ammatuna M, Inglese MG, Manzi R, Prada A, Persiani L, Santinami M, Santoro N, Cascinelli N (1994) Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer 73:483-492.
13. 13. Brouckaert P, Everaerdt B, Libert C, Takahashi N, Cauwels A, Fiers W (1993) Strategies to broaden the therapeutic margin of tumor necrosis factor. In Fiers W, Buurman WA (eds) Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance, Karger, Basel, pp. 226-232.
14. 14. Brouckaert P, Ameloot P, Cauwels A, Everaerdt B, Libert C, Takahashi N, Van Molle W, Fiers W (1994) Receptor-selective mutants of tumor necrosis factor in the therapy of cancer: preclinical studies. Circ Shock 43:185-190.
15. 15. Van Ostade X, Tavernier J, Fiers W (1994) Structure-activity studies of tumour necrosis factors. Prot Eng 7:5-22.
16. 16. Menart V, Kus B, Novaković S, Serša G, Gaberc-Porekar V, Harb V, Miličić S, Štale A (1996) Searching for new TNF-α analogues having potential application in cancer therapy. Pflügers Arch - Eur J Physiol 431:R233-R234.
17. 17. Menart V, Gaberc-Porekar V, Harb V (1994) Metal-affinity separations of model proteins having differently spaced clusters of histidine residues. In Pyle DL (ed) Separations for Biotechnology, 3:303-313.
18. 18. Kuroda K, Miyata K, Shikama H, Kawagoe T, Nishimura K, Takeda K, Sakae N, Kato M (1995) Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice. Int J Cancer 63:152-157.
19. 19. Beutler B, Cerami A (1988) Tumor necrosis cachexia, shock and inflammation: A common mediator. Annu Rev Biochem 57:505-518.
20. 20. Jäättelä M (1991) Biology of disease. Biological activities and mechanisms of action of tumor necrosis factor-α/cachectin. Lab Invest 64:724-742.
21. 21. Novaković S, Boldog I (1994) In vitro TNF-α production and in vivo alteration of TNF-α RNA in mouse peritoneal macrophages after treatment with different bacterial derived agents. Cancer Lett 81:99-109.
22. 22. de Kossodo S, Moore R, Gschmeissner S, East N, Upton C, Balkwile FR (1995) Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumor necrosis. Br J Cancer 72:1165-1172.
23. 23. Fukumura D, Salehi HA, Witwer B, Tuma RF, Melder RJ, Jain RK (1995) Tumor necrosis factor α-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain. Cancer Res 55:484-4829.
24. 24. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
25. 25. Belev TN, Singh M, McCarthy EG (1991) A Fully Modular Vector System for the Optimization of Gene Expression in Escherichia coli. Plasmid 26:147-150.
26. 26. Kunkel TA, Roberts JD, Zakour RA (1987) Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection. In Colowick SP, Kaplan NO (eds) Methods in Enzymology 154: Wu R, Grossman L (eds) Recombinant DNA, Part E, Academic Press, Inc. San Diego, pp. 367-382.
27. 27. Kus B, Serša G, Novaković S, Urbančič J, Štale A (1993) Modification of TNF-α pharmacokinetics in Sa-1 tumor-bearing mice. Int J Cancer 55:110-114.
28. 28. Fujita F, Fujita M, Taguchi T, Shimozuma K, Sakamoto Y, Kimoto Y, Hirai T (1993) Multifunctional analysis of parameters influencing chemosensitivity of human cancer xenografts in nude mice. Int J Cancer 43:637-644.